ACADIA PHARMACEUTICALS INC. Prepaid Expense and Other Assets, Current
ACADIA PHARMACEUTICALS INC. (ACAD) had Prepaid Expense and Other Assets, Current of $69.37 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-05
- 2026-06-30: Prepaid Expense and Other Assets, Current $69.37M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $59.53M.
- 2016-12-31: Prepaid Expense and Other Assets, Current $7.55M.
- 2016-09-30: Prepaid Expense and Other Assets, Current $5.11M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $69.37M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $59.53M 10-Q · filed 2026-08-05 | |
| 2016-12-31 | $7.55M 10-K · filed 2017-02-28 | |
| 2016-09-30 | $5.11M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $6.84M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $4.33M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $2.22M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $1.95M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $1.11M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $1.26M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $1.17M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $2.13M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $3.08M 10-Q · filed 2014-08-05 | |
| 2013-12-31 | $1.82M 10-K · filed 2015-02-26 | $2.57M 10-K · filed 2014-02-27 |
| 2013-09-30 | $2.50M 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $1.31M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $1.52M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $581.00K 10-K · filed 2014-02-27 | |
| 2012-09-30 | $627.00K 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $426.00K 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $463.00K 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $901.00K 10-K · filed 2013-03-12 | |
| 2011-09-30 | $613.00K 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $654.00K 10-Q · filed 2011-08-10 | |
| 2010-12-31 | $762.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |